Pricing Log in Create free account
Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS
−61.5%
Free cash flow
−92.6%

Quarter to June 2026, against a year earlier

64.23 2.31 +3.73%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Vaxcyte, Inc. (PCVX) valuation and DCF model

What the price implies · reverse DCF

Vaxcyte, Inc. is not valued here: free cash flow is negative and there is no revenue to read the price through.

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Biotechnology).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/B 3.28× 3.28× 3.28× 0% above 2.05× 60% above

PCVX trades at 3.28× P/B, against a 10-year average of 3.28× (range 3.28×–3.28×). Re-rating to the average implies $64.23 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.